Cancer stem cells as a target population for drug discovery

References

• 1 Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108(3), 479–485 (2013).
  Medline CASGoogle Scholar
• 2 Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 501(7467), 328–337 (2013).
  Medline CASGoogle Scholar
• 3 Greaves M, Maley CC. Clonal evolution in cancer. Nature 481(7381), 306–313 (2012).
  Medline CASGoogle Scholar
• 4 Nowell PC. The clonal evolution of tumor cell populations. Science 194(4260), 23–28 (1976).
  Medline CASGoogle Scholar
• 5 Burrell RA, Mcgranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467), 338–345 (2013).
  Medline CASGoogle Scholar
• 6 Valent P, Bonnet D, De Maria R et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12(11), 767–775 (2012).
  Medline CASGoogle Scholar
• 7 Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10(6), 717–728 (2012).
  Medline CASGoogle Scholar
• 8 Vermeulen L, De Sousa E Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 13(2), e83–e89 (2012).
  MedlineGoogle Scholar
• 9 Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 14(3), 275–291 (2014).
  Medline CASGoogle Scholar
• 10 Greaves M. Cancer stem cells as ‘units of selection’. Evol. Appl. 6(1), 102–108 (2013).
  MedlineGoogle Scholar
• 11 Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17(3), 313–319 (2011).
  Medline CASGoogle Scholar
• 12 Tirino V, Desiderio V, Paino F et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 27(1), 13–24 (2013).
  Medline CASGoogle Scholar
• 13 Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br. J. Cancer 103(4), 439–445 (2010).
  Medline CASGoogle Scholar
• 14 Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198(3), 281–293 (2012).
  Medline CASGoogle Scholar
• 15 Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730–737 (1997).
  Medline CASGoogle Scholar
• 16 Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396–401 (2004).
  Medline CASGoogle Scholar
• 17 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983–3988 (2003).
  Medline CASGoogle Scholar
• 18 Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23), 10946–10951 (2005).
  Medline CASGoogle Scholar
• 19 Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67(3), 1030–1037 (2007).
  Medline CASGoogle Scholar
• 20 Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104(3), 973–978 (2007).
  Medline CASGoogle Scholar
• 21 Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 451(7176), 345–349 (2008).
  Medline CASGoogle Scholar
• 22 Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111–115 (2007).
  Medline CASGoogle Scholar
• 23 Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120(1), 41–50 (2010).
  Medline CASGoogle Scholar
• 24 Kitambi SS, Chandrasekar G. Stem cells: a model for screening, discovery and development of drugs. Stem Cells Cloning 4, 51–59 (2011).
  Medline CASGoogle Scholar
• 25 Zhu S, Wurdak H, Schultz PG. Directed embryonic stem cell differentiation with small molecules. Future Med. Chem. 2(6), 965–973 (2010).
  CASGoogle Scholar
• 26 Lyssiotis CA, Lairson LL, Boitano AE, Wurdak H, Zhu S, Schultz PG. Chemical control of stem cell fate and developmental potential. Angew. Chem. Int. Ed. Engl. 50(1), 200–242 (2011).
  Medline CASGoogle Scholar
• 27 Verga Falzacappa MV, Ronchini C, Reavie LB, Pelicci PG. Regulation of self-renewal in normal and cancer stem cells. FEBS J. 279(19), 3559–3572 (2012).
  Medline CASGoogle Scholar
• 28 Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9(9), 2450–2457 (2010).
  Medline CASGoogle Scholar
• 29 Merlos-Suarez A, Barriga FM, Jung P et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8(5), 511–524 (2011).
  Medline CASGoogle Scholar
• 30 O'brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123), 106–110 (2007).
  MedlineGoogle Scholar
• 31 Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 7(2), 292–306 (2011).
  Medline CASGoogle Scholar
• 32 Luo Y, Dallaglio K, Chen Y et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30(10), 2100–2113 (2012).
  Medline CASGoogle Scholar
• 33 Mao P, Joshi K, Li J et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl Acad. Sci. USA 110(21), 8644–8649 (2013).
  Medline CASGoogle Scholar
• 34 Kryczek I, Liu S, Roh M et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 130(1), 29–39 (2012).
  Medline CASGoogle Scholar
• 35 Fleischman AG. ALDH marks leukemia stem cell. Blood 119(15), 3376–3377 (2012).
  Medline CASGoogle Scholar
• 36 Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco. Targets Ther. 6, 1347–1361 (2013).
  Medline CASGoogle Scholar
• 37 Grimm M, Krimmel M, Polligkeit J et al. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur. J. Cancer 48(17), 3186–3197 (2012).
  Medline CASGoogle Scholar
• 38 Ma J, Frank MH. Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med. Chem. 10(2), 131–136 (2010).
  Medline CASGoogle Scholar
• 39 Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118(6), 2111–2120 (2008).
  Medline CASGoogle Scholar
• 40 Grosse-Gehling P, Fargeas CA, Dittfeld C et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J. Pathol. 229(3), 355–378 (2013).
  Medline CASGoogle Scholar
• 41 Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood 119(2), 494–502 (2012).
  Medline CASGoogle Scholar
• 42 Williams BA, Wang XH, Keating A. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy 12(7), 951–960 (2010).
  Medline CASGoogle Scholar
• 43 Dey D, Saxena M, Paranjape AN et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS ONE 4(4), e5329 (2009).
  MedlineGoogle Scholar
• 44 Dong Q, Wang D, Bandyopadhyay A et al. Mammospheres from murine mammary stem cell-enriched basal cells: clonal characteristics and repopulating potential. Stem Cell Res. 10(3), 396–404 (2013).
  Medline CASGoogle Scholar
• 45 Deleyrolle LP, Reynolds BA. Isolation, expansion, and differentiation of adult mammalian neural stem and progenitor cells using the neurosphere assay. Methods Mol. Biol. 549, 91–101 (2009).
  Medline CASGoogle Scholar
• 46 Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. Curr. Opin. Pharmacol. 10(4), 380–384 (2010).
  Medline CASGoogle Scholar
• 47 Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 5(11), 899–904 (2005).
  Medline CASGoogle Scholar
• 48 Sell S. On the stem cell origin of cancer. Am. J. Pathol. 176(6), 2584–2494 (2010).
  Medline CASGoogle Scholar
• 49 Shlush LI, Zandi S, Mitchell A et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506(7488), 328–333 (2014).
  Medline CASGoogle Scholar
• 50 Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 22(3), 457–472 (2012).
  Medline CASGoogle Scholar
• 51 Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell 116(5), 639–648 (2004).
  Medline CASGoogle Scholar
• 52 Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22(5–6), 396–403 (2012).
  Medline CASGoogle Scholar
• 53 Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 341(1), 63–72 (2013).
  Medline CASGoogle Scholar
• 54 Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol. Oncol. 6(6), 620–636 (2012).
  Medline CASGoogle Scholar
• 55 Lu X, Kang Y. Cell fusion hypothesis of the cancer stem cell. Adv. Exp. Med. Biol. 714, 129–140 (2011).
  Medline CASGoogle Scholar
• 56 Sanges D, Lluis F, Cosma MP. Cell-fusion-mediated reprogramming: pluripotency or transdifferentiation? Implications for regenerative medicine. Adv. Exp. Med. Biol. 713, 137–159 (2011).
  Medline CASGoogle Scholar
• 57 Lluis F, Cosma MP. Cell-fusion-mediated somatic-cell reprogramming: a mechanism for tissue regeneration. J. Cell. Physiol. 223(1), 6–13 (2010).
  Medline CASGoogle Scholar
• 58 Pawelek JM, Chakraborty AK. The cancer cell–leukocyte fusion theory of metastasis. Adv. Cancer Res. 101, 397–444 (2008).
  Medline CASGoogle Scholar
• 59 Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 306(5701), 1568–1571 (2004).
  Medline CASGoogle Scholar
• 60 Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat. Rev. Cancer 8(5), 377–386 (2008).
  Medline CASGoogle Scholar
• 61 Aractingi S, Kanitakis J, Euvrard S et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res. 65(5), 1755–1760 (2005).
  Medline CASGoogle Scholar
• 62 Lazova R, Laberge GS, Duvall E et al. A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer. PLoS ONE 8(6), e66731 (2013).
  Medline CASGoogle Scholar
• 63 Maund SL, Cramer SD. The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev. 7(2), 307–314 (2011).
  Medline CASGoogle Scholar
• 64 Lairson LL, Lyssiotis CA, Zhu S, Schultz PG. Small molecule-based approaches to adult stem cell therapies. Annu. Rev. Pharmacol. Toxicol. 53, 107–125 (2013).
  Medline CASGoogle Scholar
• 65 Chen J, Li Y, Yu TS et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412), 522–526 (2012).
  Medline CASGoogle Scholar
• 66 Abubaker K, Latifi A, Luwor R et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer 12, 24 (2013).
  Medline CASGoogle Scholar
• 67 Ghiaur G, Gerber J, Jones RJ. Concise review: Cancer stem cells and minimal residual disease. Stem Cells 30(1), 89–93 (2012).
  Medline CASGoogle Scholar
• 68 Lin WC, Rajbhandari N, Liu C et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 73(6), 1821–1830 (2013).
  Medline CASGoogle Scholar
• 69 Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. Cancer stem cells as a predictive factor in radiotherapy. Semin. Radiat. Oncol. 22(2), 151–174 (2012).
  MedlineGoogle Scholar
• 70 Emmink BL, Van Houdt WJ, Vries RG et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 141(1), 269–278 (2011).
  Medline CASGoogle Scholar
• 71 Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14(3), 306–321 (2014).
  Medline CASGoogle Scholar
• 72 Liu H, Patel MR, Prescher JA et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107(42), 18115–18120 (2010).
  Medline CASGoogle Scholar
• 73 Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32(35), 4057–4063 (2013).
  Medline CASGoogle Scholar
• 74 Cheng L, Huang Z, Zhou W et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153(1), 139–152 (2013).
  Medline CASGoogle Scholar
• 75 Coni S, Infante P, Gulino A. Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection. Biochem. Pharmacol. 85(5), 623–628 (2013).
  Medline CASGoogle Scholar
• 76 Dodge ME, Lum L. Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. Annu. Rev. Pharmacol. Toxicol. 51, 289–310 (2011).
  Medline CASGoogle Scholar
• 77 Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr. Opin. Cell Biol. 25(2), 254–264 (2013).
  Medline CASGoogle Scholar
• 78 Santini R, Vinci MC, Pandolfi S et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 30(9), 1808–1818 (2012).
  Medline CASGoogle Scholar
• 79 Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8(2), 97–106 (2011).
  Medline CASGoogle Scholar
• 80 Van Den Hoogen C, Van Der Horst G, Cheung H, Buijs JT, Pelger RC, Van Der Pluijm G. Integrin alphav expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am. J. Pathol. 179(5), 2559–2568 (2011).
  Medline CASGoogle Scholar
• 81 Lu X, Mu E, Wei Y et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20(6), 701–714 (2011).
  Medline CASGoogle Scholar
• 82 Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc. Natl Acad. Sci. USA 108(26), 10544–10549 (2011).
  Medline CASGoogle Scholar
• 83 Hahn CK, Berchuck JE, Ross KN et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16(4), 281–294 (2009).
  Medline CASGoogle Scholar
• 84 Stechishin OD, Luchman HA, Ruan Y et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro. Oncol. 15(2), 198–207 (2013).
  Medline CASGoogle Scholar
• 85 Saito Y, Yuki H, Kuratani M et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci. Transl. Med. 5(181), 181ra152 (2013).
  Google Scholar
• 86 Zhu S, Wurdak H, Wang J et al. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4(5), 416–426 (2009).
  Medline CASGoogle Scholar
• 87 Pabst C, Krosl J, Fares I et al. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat. Methods doi:10.1038/nmeth.2847 (2014) (Epub ahead of print). 
  MedlineGoogle Scholar
• 88 Zhao S, Kanno Y, Nakayama M, Makimura M, Ohara S, Inouye Y. Activation of the aryl hydrocarbon receptor represses mammosphere formation in MCF-7 cells. Cancer Lett. 317(2), 192–198 (2012).
  Medline CASGoogle Scholar
• 89 Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 5(11), e13831 (2010).
  MedlineGoogle Scholar
• 90 Bunaciu RP, Yen A. Activation of the aryl hydrocarbon receptor AhR Promotes retinoic acid-induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res. 71(6), 2371–2380 (2011).
  Medline CASGoogle Scholar
• 91 Dave B, Landis MD, Tweardy DJ et al. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS ONE 7(8), e30207 (2012).
  Medline CASGoogle Scholar
• 92 Hahn CK, Ross KN, Warrington IM et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc. Natl Acad. Sci. USA 105(28), 9751–9756 (2008).
  Medline CASGoogle Scholar
• 93 Kreso A, Van Galen P, Pedley NM et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20(1), 29–36 (2014).
  Medline CASGoogle Scholar
• 94 Wurdak H, Zhu S, Romero A et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 6(1), 37–47 (2010).
  Medline CASGoogle Scholar
• 95 Zuber J, Shi J, Wang E et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370), 524–528 (2011).
  Medline CASGoogle Scholar
• 96 Herrmann H, Blatt K, Shi J et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 3(12), 1588–1599 (2012).
  MedlineGoogle Scholar
• 97 Filippakopoulos P, Qi J, Picaud S et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067–1073 (2010).
  Medline CASGoogle Scholar
• 98 Lamoureux F, Baud'huin M, Rodriguez Calleja L et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 5, 3511 (2014).
  MedlineGoogle Scholar
• 99 Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin. Cancer Res. 18(20), 5562–5571 (2012).
  Medline CASGoogle Scholar
• 100 Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390), 474–478 (2012).
  Medline CASGoogle Scholar
• 101 Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553–567 (2010).
  Medline CASGoogle Scholar
• 102 Lu C, Venneti S, Akalin A et al. Induction of sarcomas by mutant IDH2. Genes Dev. 27(18), 1986–1998 (2013).
  Medline CASGoogle Scholar
• 103 Li Z, Bao S, Wu Q et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6), 501–513 (2009).
  Medline CASGoogle Scholar
• 104 Soeda A, Park M, Lee D et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28(45), 3949–3959 (2009).
  Medline CASGoogle Scholar
• 105 Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8(4), 399–411 (2011).
  Medline CASGoogle Scholar
• 106 Xiang L, Gilkes DM, Chaturvedi P et al. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J. Mol. Med. (Berlin) 92(2), 151–164 (2014).
  Medline CASGoogle Scholar
• 107 Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res. Treat. 133(1), 75–87 (2012).
  Medline CASGoogle Scholar
• 108 Liu P, Kumar IS, Brown S et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br. J. Cancer 109(7), 1876–1885 (2013).
  Medline CASGoogle Scholar
• 109 Chaturvedi A, Araujo Cruz MM, Jyotsana N et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122(16), 2877–2887 (2013).
  Medline CASGoogle Scholar
• 110 Kats LM, Reschke M, Taulli R et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14(3), 329–341 (2014).
  Medline CASGoogle Scholar
• 111 Kim RJ, Park JR, Roh KJ et al. High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett. 333(1), 18–31 (2013).
  Medline CASGoogle Scholar
• 112 Wu X, Schultz PG. Synthesis at the interface of chemistry and biology. J. Am. Chem. Soc. 131(35), 12497–12515 (2009).
  Medline CASGoogle Scholar
• 113 Wurdak H. Exploring the cancer stem cell phenotype with high-throughput screening applications. Future Med. Chem. 4(10), 1229–1241 (2012).
  CASGoogle Scholar
• 114 Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645–659 (2009).
  Medline CASGoogle Scholar
• 115 Atkinson JM, Shelat AA, Carcaboso AM et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3), 384–399 (2011).
  Medline CASGoogle Scholar
• 116 Danovi D, Folarin A, Gogolok S et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS ONE 8(10), e77053 (2013).
  Medline CASGoogle Scholar
• 117 Grinshtein N, Datti A, Fujitani M et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 71(4), 1385–1395 (2011).
  Medline CASGoogle Scholar
• 118 Mcdermott SP, Eppert K, Notta F et al. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood 119(5), 1200–1207 (2012).
  Medline CASGoogle Scholar
• 119 O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin. Cancer Res. 16(12), 3113–3120 (2010).
  MedlineGoogle Scholar
• 120 Ablain J, Rice K, Soilihi H, De Reynies A, Minucci S, De The H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat. Med. 20(2), 167–174 (2014).
  Medline CASGoogle Scholar
• 121 Sachlos E, Risueno RM, Laronde S et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149(6), 1284–1297 (2012).
  Medline CASGoogle Scholar
• 122 Krause DS, Fulzele K, Catic A et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat. Med. 19(11), 1513–1517 (2013).
  Medline CASGoogle Scholar
• 123 Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN. Twisted tango: brain tumor neurovascular interactions. Nat. Neurosci. 14(11), 1375–1381 (2011).
  Medline CASGoogle Scholar
• 124 Yang ZJ, Wechsler-Reya RJ. Hit ‘em where they live: targeting the cancer stem cell niche. Cancer Cell 11(1), 3–5 (2007).
  Medline CASGoogle Scholar
• 125 Koch U, Lehal R, Radtke F. Stem cells living with a Notch. Development 140(4), 689–704 (2013).
  Medline CASGoogle Scholar
• 126 Labarge MA. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res. 16(12), 3121–3129 (2010).
  Medline CASGoogle Scholar
• 127 Fael Al-Mayhani TM, Ball SL, Zhao JW et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods 176(2), 192–199 (2009).
  Medline CASGoogle Scholar
• 128 Kawaguchi-Ihara N, Murohashi I, Nara N, Tohda S. Promotion of the self-renewal capacity of human acute leukemia cells by Wnt3A. Anticancer Res. 28(5A), 2701–2704 (2008).
  Medline CASGoogle Scholar
• 129 Ohata H, Ishiguro T, Aihara Y et al. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res. 72(19), 5101–5110 (2012).
  Medline CASGoogle Scholar
• 130 Sims-Mourtada J, Niamat RA, Samuel S, Eskridge C, Kmiec EB. Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds. Int. J. Nanomedicine 9, 995–1003 (2014).
  MedlineGoogle Scholar
• 131 Carmody LC, Germain AR, Verplank L et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J. Biomol. Screen 17(9), 1204–1210 (2012).
  MedlineGoogle Scholar
• 132 Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4(6), 568–580 (2009).
  Medline CASGoogle Scholar
• 133 Cavnar SP, Salomonsson E, Luker KE, Luker GD, Takayama S. Transfer, imaging, and analysis plate for facile handling of 384 hanging drop 3D tissue spheroids. J. Lab. Autom. 19(2), 208–214 (2014).
  MedlineGoogle Scholar
• 134 Mathews LA, Keller JM, Goodwin BL et al. A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells. J. Biomol. Screen 17(9), 1231–1242 (2012).
  MedlineGoogle Scholar
• 135 Germain AR, Carmody LC, Morgan B et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg. Med. Chem. Lett. 22(10), 3571–3574 (2012).
  Medline CASGoogle Scholar
• 136 Yoo BH, Axlund SD, Kabos P et al. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J. Biomol. Screen. 17(9), 1211–1220 (2012).
  MedlineGoogle Scholar
• 137 Barbaric I, Jones M, Harley DJ, Gokhale PJ, Andrews PW. High-content screening for chemical modulators of embryonal carcinoma cell differentiation and survival. J. Biomol. Screen. 16(6), 603–617 (2011).
  Medline CASGoogle Scholar
• 138 Visnyei K, Onodera H, Damoiseaux R et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol. Cancer Ther. 10(10), 1818–1828 (2011).
  Medline CASGoogle Scholar
• 139 Johnson K, Zhu S, Tremblay MS et al. A stem cell-based approach to cartilage repair. Science 336(6082), 717–721 (2012).
  Medline CASGoogle Scholar
• 140 Leslie BJ, Hergenrother PJ. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem. Soc. Rev. 37(7), 1347–1360 (2008).
  Medline CASGoogle Scholar
• 141 Schenone M, Dancik V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9(4), 232–240 (2013).
  Medline CASGoogle Scholar
• 142 Burdine L, Kodadek T. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11(5), 593–597 (2004).
  Medline CASGoogle Scholar
• 143 Ziegler S, Pries V, Hedberg C, Waldmann H. Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 52(10), 2744–2792 (2013).
  Medline CASGoogle Scholar
• 144 Chan JN, Nislow C, Emili A. Recent advances and method development for drug target identification. Trends Pharmacol. Sci. 31(2), 82–88 (2010).
  Medline CASGoogle Scholar
• 145 Kahsai AW, Zhu S, Wardrop DJ, Lane WS, Fenteany G. Quinocarmycin analog DX-52–51 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. Chem. Biol. 13(9), 973–983 (2006).
  Medline CASGoogle Scholar
• 146 Wurdak H, Zhu S, Min KH et al. A small molecule accelerates neuronal differentiation in the adult rat. Proc. Natl Acad. Sci. USA 107(38), 16542–16547 (2010).
  Medline CASGoogle Scholar
• 147 Denysenko T, Gennero L, Juenemann C et al. Heterogeneous phenotype of human glioblastoma: in vitro study. Cell Biochem. Funct. 32(2), 164–176 (2014).
  Medline CASGoogle Scholar
• 148 Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1), 98–110 (2010).
  Medline CASGoogle Scholar
• 149 Brennan CW, Verhaak RG, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 155(2), 462–477 (2013).
  Medline CASGoogle Scholar
• 150 Klco JM, Spencer DH, Miller CA et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25(3), 379–392 (2014).
  Medline CASGoogle Scholar
• 151 Topol EJ. Individualized medicine from prewomb to tomb. Cell 157(1), 241–253 (2014).
  Medline CASGoogle Scholar
• 152 Kretzschmar K, Watt FM. Lineage tracing. Cell 148(1–2), 33–45 (2012).
  Medline CASGoogle Scholar
• 153 Castellone MD, Laatikainen LE, Laurila JP et al. Brief report: mesenchymal stromal cell atrophy in coculture increases aggressiveness of transformed cells. Stem Cells 31(6), 1218–1223 (2013).
  Medline CASGoogle Scholar
• 154 Chaturvedi P, Gilkes DM, Wong CC et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest. 123(1), 189–205 (2013).
  Medline CASGoogle Scholar
• 155 Bengsch F, Buck A, Gunther SC et al. Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33(36), 4474–4484 (2014).
  Medline CASGoogle Scholar
• 156 Ranga A, Gjorevski N, Lutolf MP. Drug discovery through stem cell-based organoid models. Adv. Drug Deliv. Rev. doi:10.1016j.addr.02.006 (2014) (Epub ahead of print). 
  MedlineGoogle Scholar
• 157 Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340(6137), 1190–1194 (2013).
  Medline CASGoogle Scholar
• 158 Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr. Opin. Genet. Dev. 24C, 68–73 (2014).
  Google Scholar
• 159 Chuang HN, Lohaus R, Hanisch UK, Binder C, Dehghani F, Pukrop T. Coculture system with an organotypic brain slice and 3D spheroid of carcinoma cells. J. Vis. Exp. doi:10.379150881 (2013) (Epub ahead of print). 
  Google Scholar
• 160 Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731–2738 (2004).
  Medline CASGoogle Scholar
• 161 Seok J, Warren HS, Cuenca AG et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110(9), 3507–3512 (2013).
  Medline CASGoogle Scholar
• 162 Brehm MA, Wiles MV, Greiner DL, Shultz LD. Generation of improved humanized mouse models for human infectious diseases. J. Immunol. Methods doi:10.1016j.jim.02.011 (2014) (Epub ahead of print). 
  MedlineGoogle Scholar
• 163 Soucek L, Whitfield JR, Sodir NM et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27(5), 504–513 (2013).
  Medline CASGoogle Scholar
• 164 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. World J. Gastroenterol. 18(12), 1286–1294 (2012).
  MedlineGoogle Scholar
• 165 Dhomen N, Reis-Filho JS, Da Rocha Dias S et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15(4), 294–303 (2009).
  Medline CASGoogle Scholar
• 166 Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 24(11), 1823–1833 (2010).
  Medline CASGoogle Scholar